Arnaud Goepfert
Vice President, Biologics Engineering Ennovate Pharma
Seminars
Thursday 9th July 2026
Next-Generation Multispecific Antibody Engineering for Patients with Inflammatory Skin Conditions Unresponsive to Dupilumab
4:00 pm
- Translate clinical non-response into protein engineering opportunities for precision immunomodulation
- Explore next-generation biologic design strategies to overcome pathway redundancy and therapeutic escape
- Dissect molecular and pathway drivers of incomplete or lost response to dupilumab to identify actionable engineering targets
